Sanofi backs out of $500m cancer alliance with Revolution
pharmaphorum
DECEMBER 9, 2022
The deal – which included a $50 million upfront payment and up to $450 million in follow-up payments – had advanced the RMC-4630 drug candidate from preclinical testing to a phase 2 trial in combination with Amgen’s first-to-market KRAS inhibitor Lumakras (sotorasib) as a treatment for KRASG12C mutated non-small cell lung cancer (NSCLC).
58 
Let's personalize your content